Next Article in Journal
Coronal and Root Canal Microbiota in Apical Periodontitis with Different PAI
Previous Article in Journal
Relationships between Wheat Development, Soil Properties, and Rhizosphere Mycobiota
Previous Article in Special Issue
Shiga Toxin-Producing Escherichia coli Strains from Romania: A Whole Genome-Based Description
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Bacterial Resistances and Sensibilities in a Tertiary Care Hospital in Romania—A Retrospective Analysis

1
Centre for Molecular Research in Nephrology and Vascular Disease, Faculty of Medicine “Victor Babes”, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
2
Discipline of Nephrology, University of Medicine and Pharmacy “Victor Babes”, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
3
“Louis Turcanu” Emergency County Hospital for Children, 300011 Timisoara, Romania
4
Microbiology Department, Multidisciplinary Research Center of Antimicrobial Resistance, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
5
Microbiology Laboratory, “Pius Brinzeu” County Clinical Emergency Hospital, 300723 Timisoara, Romania
6
Discipline of Cardiology, University of Medicine and Pharmacy “Victor Babes”, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
*
Author to whom correspondence should be addressed.
Microorganisms 2024, 12(8), 1517; https://doi.org/10.3390/microorganisms12081517
Submission received: 24 June 2024 / Revised: 20 July 2024 / Accepted: 22 July 2024 / Published: 24 July 2024
(This article belongs to the Special Issue State-of-the-Art Parasitic and Bacterial Infections in Romania 2.0)

Abstract

:
The increase in bacterial resistance is currently a global burden for the health care system. In order to evaluate the resistance rates of several bacteria from the most encountered cultures in clinical practice, we performed a retrospective analysis of all of the positive cultures from the year 2021 in a tertiary care hospital in Romania. Our analysis captured 3299 positive cultures. The median age of the patients was 62 years (IQR: 41–71 years old) with a slight predominance among females (53.1%). Overall, the most common cultures were urocultures, wound secretion cultures and blood cultures, and the most common identified bacteria were Escherichia coli, Staphylococcus aureus and Klebsiella spp. Positive cultures with the highest resistance rates were found in the bronchial aspirate cultures, catheter tip cultures, urocultures and blood cultures. Escherichia coli (n = 996) had the highest resistance to ampicillin (19.8%) and trimetoprim-sulfametoxazole (16.4%), while Staphylococcus aureus (n = 698) presented the highest resistance rates to clindamycin (27.4%) and oxaciline (19.7%). Klebsiella (n = 481) presented the highest resistance rates to piperaciline-tazobactam (25.2%) and ampicillin (20.4%), whereas Acinetobacter baumanii (n = 123) presented a resistance rate of more than 50% to carbapenems, gentamicin, ciprofloxacin and ceftazidime. The aim of our study was to identify bacterial resistance rates in order to provide updated clinical data to guide physicians in choosing the best empirical antibiotic treatment, especially in the west part of Romania.

1. Introduction

Antimicrobial resistance is one of the hottest topics of this millennium. Current studies show an ascending trend of overall bacterial resistance, which extends even to “reserve antibiotics”, with impacts on quality of life, hospitalization and mortality [1,2,3,4,5,6,7]. The Review on Antimicrobial Resistance from the United Kingdom (UK) Government, World Health Organization (WHO) and many other organizations agree that there is an imperative need for a mutual approach in order to reduce bacterial resistance [1,8,9,10,11,12]. The latest predictions suggest that by 2050, resistant bacteria could kill more than 10 million people per year [1].
Antimicrobial resistance is heterogeneous regarding geographic regions. The first world-wide estimates on the burden of antimicrobial resistance were published in 2022 in Lancet [1]. This study estimated that almost 5 million people died in 2019 due to bacterial infections, and 25% of these patients presented a death attributable to bacterial antimicrobial resistance [1]. The pathogens identified as the leading causes of death were Escherichia coli, Staphylococcus aureus, Klebsiella pneumonia, Streptococcus pneumonia, Acinetobacter baumanii and Pseudomonas aeruginosa [1]. In a published study on eight bacterial pathogens and 16 pathogen–drug combinations from the European Union, Cassini et al. identified the same germs as the leading causes of antimicrobial resistance-associated mortality [2].
Data from Romania are scarce regarding bacterial resistance, and the majority of studies focus on one germ or just one site of infection [13,14,15,16,17,18]. On the other hand, hospital-associated infection, which is the leading cause of multidrug-resistant infections, seems to be underreported in Romania [16].
In order to address this issue and create a better image of bacterial resistances and sensibilities in Romania, we performed a retrospective analysis of all of the positive cultures from a tertiary care hospital in the west part of Romania. The data were extracted over twelve months, representing the year 2021. We present the sensibilities and resistances stratified by positive cultures and by the identified bacteria.

2. Materials and Methods

We performed a cross-sectional retrospective analysis of all positive cultures from the Emergency County Hospital “Pius Brinzeu” from Timisoara, Romania from the year 2021. This study was performed in accordance with the Ethics Code of the World Medical Association and the “Pius Brinzeu” Emergency County Hospital, and the Timisoara Ethics Committee approved this study (466/17 May 2024). This study followed the Declaration of Helsinki recommendations. The patients signed an informed consent form upon admission to the hospital. We used the electronic data system in order to extract all of the positive cultures. We recorded the age, gender, the culture type and the identified bacterial pathogen. In addition, we extracted the sensibilities and resistance rates to several tested antibiotics.

2.1. Sample Collection

The samples were collected over a 12-month period, comprising all of the positive cultures from the admitted patients used to confirm the clinical suspicion of infection. Cultures were performed according to the working protocol of the Microbiology Laboratory of Emergency County Hospital “Pius Brinzeu” in Timisoara.

2.2. Bacterial Identification and Antibiotic Testing

Cultures were performed according to the working protocol of the Microbiology Laboratory of Emergency County Hospital “Pius Brinzeu” from Timisoara. All isolates were first identified using the VITEK® 2 GN and VITEK® 2 GP ID cards (BioMérieux, Marcy l’Etoile, France). For Staphylococcus aureus and Streptococcus spp. identification, latex agglutination tests were also conducted using the Staphytect Plus and Streptococcal Grouping kit (Thermo Fischer Scientic). Antimicrobial susceptibility tests (AST) were performed using the VITEK 2 GN AST-N222 and VITEK 2 AST GP 67 cards (BioMérieux, Marcy l’Etoile, France) by the determination of the minimum inhibitory concentration (MIC) and the Kirby–Bauer disk diffusion method [19,20]. Classification into resistance phenotypes was performed according to the Clinical Laboratory and Standards Institute (CLSI) criteria [20]. We used the following reference strains: Escherichia coli ATCC 25922, Klebsiella pneumoniae ATCC 1705, Pseudomonas aeruginosa ATCC 27853 and Staphylococcus aureus ATCC 25923. For the Kirby–Bauer disk diffusion method, antibiotics from Thermo Fischer Scientific were used. The concentrations of the antibiotic disks were chosen according to the CLSI 2021 standard [20].

2.3. Culture Types and Identified Bacteria

The identified cultures were blood cultures, wound secretion cultures, peritoneal liquid cultures, cervical cultures, vaginal cultures, urocultures, sputum cultures, bronchial aspirate cultures, catheter tip cultures and abcess cultures.
The germs that we identified and evaluated were Streptococcus, Pseudomonas aeruginosa, Enterobacter spp., Staphylococcus aureus, Bacillus cereus, Acinetobacter baumanii, Serratia marcesnens, Providencia, Proteus mirabilis, Corynebacterium, Citrobacter, Escherichia coli and Klebsiella spp.
The outcomes of our study are the bacteria distribution regarding the culture type and the incidence of certain antibiotics’ resistance and sensibilities.
The recorded antibiotics are presented in Table 1.

2.4. Statistical Analysis

Data are presented as numbers and percentages for categorical variables. The age is presented as median (M) and interquartile range (IQR) because the age distribution was non-Gaussian. The evaluation of distribution was performed using Shapiro–Wilk test. The test used was the Chi-square test for categorical variables. A p-value less than 0.05 was considered statistically significant. The analysis was performed using MedCalc® Statistical Software version 22.021 (MedCalc Software Ltd., Ostend, Belgium; https://www.medcalc.org; Accessed on 19 May 2024). In the first part of the analysis, we evaluated the incidences of sensibilities and resistance stratified by the culture type, and in the second one, we stratified the data by bacterial type.
One should mention that the antibiograms were not uniform regarding bacteria, and not even for the same bacteria. For instance, Escherichia coli may not be tested for the same antibiotic panel in different patients; Klebsiella and Staphylococcus aureus were tested for different antibiotics. One should keep in mind these aspects when interpreting the results. All of the percentages refer to the entire number of bacteria.

3. Results

3.1. Age Distribution

During the year 2021, the total number of admissions in our hospital was 41,027. The number of positive cultures was 3658. The median age of patients with positive cultures was 62 years (IQR: 41–71 years) with a slight predominance in the female gender (53.1%). A number of 317 positive cultures were identified in children, with a median age of 2 years (IQR = 0–8 years). We stratified the ages of the patients by decades, and the extended results are presented in Table 2.

3.2. Culture and Bacteria Distribution

We identified the number of cultures stratified by the type of the cultures as presented in the Materials and Methods Section. Overall, out of the 3658 positive cultures identified over the twelve-month period of this study, we excluded 320 cultures from the current analysis due to the heterogeneous distribution across ages (pharyngeal exudates, nasal exudates, tegument cultures, amniotic liquid cultures, etc.). In this analysis, the total number of studied cultures was 3338. The most common positive cultures were the urocultures, wound secretion cultures and blood cultures, accounting for 73.12%.
We evaluated the distributions of the identified germs, with the most common ones being Escherichia coli, Staphylococcus aureus and Klebsiella spp. (65.14%). We retrieved data regarding 3299 bacteria. We excluded positive fungal cultures from our evaluation.
Bacteria distribution regarding culture type was different. For instance, in blood cultures, the most common identified germ was Staphylococcus aureus—as also seen in the wound secretion cultures—while in the urocultures, the most common one was Escherichia coli. The extended results are presented in Table 3.

3.3. Resistance Rates and Sensibilities Stratified by Cultures

The sensibilities and resistance rates stratified by cultures are presented in Supplementary Tables S1 and S2.
The overall resistance rates were low, ranging from 0% (vancomycin and linezolid) to 16.9% (ciprofloxacin). The highest resistance rates were found in bronchial aspirate cultures, catheter tip cultures, urocultures and blood cultures—as shown in Figure 1. For instance, in the bronchial aspirate cultures, the resistance rates for gentamycin and ceftazidime (p < 0.05) were higher than 30%, while penem resistance rates were encountered in over 25% of the cultures (p < 0.05). The catheter tip cultures presented the highest resistance rates for gentamycin—35.7%—followed by ciprofloxacin (42.9%) and levofloxacin (31%) (p < 0.05). The urocultures had the highest resistance rates for ciprofloxacin—19%—and ampicillin—18% (p < 0.05). The blood cultures were most likely resistant to gentamycin—19.2%—and ciprofloxacin—21.1% (p < 0.05).
As expected, the cultures with the highest overall resistance rates presented the lowest sensibilities and vice versa—as seen in Supplemental Table S2.

3.4. Resistance Rates and Sensibilities Stratified by Bacteria

To complete the analysis, we evaluated the sensibilities and resistance rates using bacterial pathogen classification—as shown in Supplemental Tables S3 and S4. Escherichia coli presented the highest resistance to ampicillin (19.8%), trimethoprim-sulfamethoxazole (16.4%) and piperacillin-tazobactam (14.5%) (p < 0.05) Staphylococcus aureus presented the highest resistance rates to clindamycin (27.4%) and oxacillin (19.7%) (p < 0.05). One should mention that no Staphylococcus aureus cultures were resistant to vancomycin nor linezolid. Klebsiella spp. presented the highest resistance rates to piperacillin-tazobactam (25.2%), ampicillin (20.4%) and cefuroxime (14.8%) (p < 0.05) Figure 2. High resistance rates were identified in Providencia (around 30% for Penems and 50% for aminoglycosides, and almost 50% for ceftazidime and piperacillin-tazobactam) (p < 0.05), Acinetobacter baumanii (>50% for penems, gentamycin, ciprofloxacin and ceftazidime) and Corynebacterium (around 50% for levofloxacin, ceftriaxone, clindamycin and ampicillin) (p < 0.05). The highest resistance rates for Pseudomonas aeruginosa were to piperacillin-tazobactam (16.9%), ceftazidime (14.6%) and imipenem (12.9%) (p < 0.05). Streptococcus spp. presented higher resistance rates only to clindamycin (24.4%) and oxacillin (7.9%) (p < 0.05). Enterobacter spp. presented higher resistance rates to ceftazidime (20%) and cefepime (15%) (p < 0.05). Proteus presented higher resistance rates to ampicillin (18.3%) and trimethoprim-sulfamethoxazole (16.9%) (p < 0.05).

4. Discussions

In this study, we evaluated the distribution of bacterial pathogens in different cultures. The aim of our analysis was to describe the trend of antimicrobial patterns in patients with bacterial infections. Thus, we stratified the positive cultures firstly by the bacterial pathogen, and secondly by the bacterial sensibility and resistance pattern in different positive cultures. This study represents the mirroring of one-year bacterial infections in the west part of Romania that focused on the resistance trends of all bacterial pathogens encountered in all age groups.
The median age of the patients was 62 years, with less than 10% being minors. For instance, Axente reported a mean age of 60 years in Romania [21], and Mayr reported 63.1 years in the USA [22].
The most common encountered positive cultures were urocultures, wound secretion cultures and blood cultures. The study by Arbune on ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Escherichia coli) from an infectious disease hospital in Romania reported a similar distribution in positive cultures [13].
Bacterial distribution following positive cultures seems to follow an international pattern, with some differences regarding certain regions. For instance, the most common identified bacteria in blood cultures was Staphylococcus aureus in Australia [23] as well as in the USA [24], while in China, Escherichia coli was the leading pathogen [25]. A recent review on urinary tract infections showed that Escherichia coli remains the most encountered bacteria in urocultures, as seen in our study [26]. Regarding wound secretion cultures, Staphylococcus aureus is the most common bacteria worldwide [27,28,29].
The culture resistance and sensibility distributions represent the highlights of our study. We identified the highest resistance rates in bronchial aspirate cultures. One should expect these results, as the bronchial aspirate culture is most likely performed in intensive care unit settings (ICU). The majority of these patients were intubated, as they were undergoing an invasive procedure, putting them at a higher risk of multidrug-resistant infection. Intensive care units are prone to multidrug-resistant bacteria due to the high use of antibiotics and even reserve antibiotics, especially in septic patients. In a recent study by Han, and even in an older one by Wroblewska on patients in the ICU setting, most of the identified microbes were multidrug resistant, with most of the bacteria being Acinetobacter, Staphylococcus, Pseudomonas and Klebsiella, just like in our study [30,31].
The high resistance rate to ciprofloxacin in positive urocultures is mainly secondary to the wide use of quinolones as a first-line agent in treating urinary tract infections in the study region. A relatively recent analysis regarding positive uroculture resistance in six countries in Eastern and Northern Europe show that countries analyzed in Eastern Europe present the highest resistance rates to ciprofloxacin (Russia and Poland) [32]. On the other hand, one should keep in mind that all of our positive cultures were in hospitalized patients and not outpatients, increasing the probability that some of the patients developed positive urocultures secondary to urine catheter insertion.
This kind of stratification regarding resistance is possibly helpful for clinicians in deciding the best empirical treatment for a patient. Identifying the most probable site of infection and considering the resistance rate to an antibiotic regarding the culture sample collected could help in deciding on a certain antibiotic treatment besides the suspected bacteria. In clinical settings, in a septic patient, the clinician should not expect an antibiogram result, but should initiate an empirical treatment as soon as possible [33,34].
The analysis of bacterial resistances is another important aspect of our study. Our data show that Escherichia coli present the highest resistance rates to ampicillin and trimethoprim-sulfamethoxazole. For instance, in a study by Draganescu from 2016, the highest resistance rates of Escherichia coli were to amoxicillin–clavulanic acid and ciprofloxacin [35]. On the other hand, recent data published by Kun Li show a much higher resistance rate for Escherichia coli, with up to 87.7% for ampicillin, more than 50% for cephalosporines and 30–35% for quinolones and aminoglycosides [25]. Regarding the global burden of bacterial antimicrobial resistance in 2019, it was estimated that the Escherichia coli resistance rate to third-generation cephalosporin and fluoroquinolones was between 20 and 30%, much higher than our findings [1].
Staphylococcus aureus presented the highest resistance rates to clindamycin and oxacillin. In a recent study by Talapan, the Staphylococcus aureus resistance rate to oxacillin was higher (39%) but closer regarding clindamycin (36%) [36]. On the other hand, in a study by Kaur, the resistance rate of methicillin-resistant Staphylococcus aureus was up to 100% for oxacillin, clindamycin, quinolones and aminoglycosides [37].
Klebsiella spp. presented the highest resistance rates to piperacillin-tazobactam (25.2%), ampicillin (20.4%) and cefuroxime (14.8%). The resistance analysis of Klebsiella from another Romanian hospital showed higher resistance rates (36% to piperacillin-tazobactam and over 50% to cephalosporins) [14]. For instance, the worldwide analysis of Klebsiella pneumoniae estimates that the resistance rate is 30–40% for pemens and 60–70% for third-generation cephalosporins [1]. The 2019 global burden analysis estimated that in Romania, more than 80% of Acinetobacter baumanii strains are resistant to penems [1], which is close to our results.
One should keep in mind that differences regarding resistance could be influenced by different sensitivities in the techniques. Regarding Romania, the results are comparable given the fact that the same identification methods are used for bacteria or for antimicrobial resistance quantification.
As already mentioned, the antibiotic resistance patterns differ from region to region. There are several factors that influence resistance, and the most common ones are represented by abnormal or abusive antibiotic use not only in patients, but even in agriculture, the food industry and through environmental contamination [38,39,40,41,42].
Our study has several limitations. First, this is a single-center study; thus, our results mainly represent our study region. The fact that this is a cross-sectional study without patient follow-up or a dynamic strain resistance evaluation is another drawback. Another important limitation is the lack of uniform antibiotic testing for the same strains. The strong points are the evaluation of an entire year of positive cultures and the relatively high number of positive cultures.

5. Conclusions

In the clinical setting, the highest frequencies of positive cultures were urocultures, wound secretion cultures and blood cultures. Our results are in concordance with previously published data, with Escherichia coli, Staphylococcus aureus and Klebsiella spp. being the most common ones. Overall, our results demonstrate lower resistance rates compared with those in the literature, especially for Escherichia coli, Staphylococcus aureus and Klebsiella spp. The clinical impact of our study is mainly local, and our results could guide clinicians in deciding on an empirical treatment when they suspect a certain infection site and/or specific bacteria. The results should be cautiously interpreted as they represent the west part of Romania. On the other hand, our results are a reflection of the current antimicrobial resistance patterns depending on the infection site and age. Larger multi-center prospective studies are needed in order to reduce the global burden of misguided antibiotic use.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/microorganisms12081517/s1, Supplemental Table S1—the distribution of resistances regarding the evaluated antibiotics stratified by cultures; Supplemental Table S2—the distribution of sensibilities regarding the evaluated antibiotics stratified by cultures; Supplemental Table S3—the distribution of resistances regarding the evaluated antibiotics stratified by bacteria; Supplemental Table S4—the distribution of sensibilities regarding the evaluated antibiotics stratified by bacteria.

Author Contributions

Conceptualization, L.C. and F.C.; Methodology, M.L. and A.M.; Software, L.C.; Validation, V.I., L.M., F.B. and A.S.; Formal Analysis, L.C.; Investigation, L.C. and F.C.; Resources, L.C., A.M, F.C., F.B. and L.M.; Data Curation, L.C.; Writing—Original Draft Preparation, L.C.; Writing—Review and Editing, all authors; Visualization, L.M.; Supervision, M.L., V.I. and A.S.; Project Administration, M.L.; Funding Acquisition, A.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

The original contributions presented in this study are included in the article/Supplementary Material, and further inquiries can be directed to the corresponding author at the e-mail address [email protected]. The raw data supporting the conclusions of this article will be made available by the authors upon request. All of the data are presented in the current form of the manuscript.

Acknowledgments

We would like to acknowledge the University of Medicine and Pharmacy “Victor Babes” in Timisoara for providing support for the article processing charges.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet 2022, 399, 629–655. [Google Scholar] [CrossRef] [PubMed]
  2. Cassini, A.; Högberg, L.D.; Plachouras, D.; Quattrocchi, A.; Hoxha, A.; Simonsen, G.S.; Colomb-Cotinat, M.; Kretzschmar, M.E.; Devleesschauwer, B.; Cecchini, M.; et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis. Lancet Infect. Dis. 2019, 19, 56–66. [Google Scholar] [CrossRef] [PubMed]
  3. Lim, C.; Takahashi, E.; Hongsuwan, M.; Wuthiekanun, V.; Thamlikitkul, V.; Hinjoy, S.; Day, N.P.; Peacock, S.J.; Limmathurotsakul, D.; Hospital, A.; et al. Epidemiology and burden of multidrug-resistant bacterial infection in a developing country. eLife 2016, 5, e18082. [Google Scholar] [CrossRef] [PubMed]
  4. Vos, T.; Lim, S.S.; Abbafati, C.; Abbas, K.M.; Abbasi, M.; Abbasifard, M.; Abbasi-Kangevari, M.; Abbastabar, H.; Abd-Allah, F.; Abdelalimet, A.; et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020, 396, 1204–1222. [Google Scholar] [CrossRef] [PubMed]
  5. Hay, S.I.; Rao, P.C.; Dolecek, C.; Day, N.P.J.; Stergachis, A.; Lopez, A.D.; Murray, C.J.L. Measuring and mapping the global burden of antimicrobial resistance. BMC Med. 2018, 16, 78. [Google Scholar] [CrossRef] [PubMed]
  6. O’Neill, J. Review on Antimicrobial Resistance; London: 2014. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. Available online: https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf (accessed on 27 May 2024).
  7. de Kraker, M.E.A.; Stewardson, A.J.; Harbarth, S. Will 10 Million people die a year due to antimicrobial resistance by 2050? PLoS Med. 2016, 13, e1002184. [Google Scholar] [CrossRef] [PubMed]
  8. National Office for Animal Health. National Office for Animal Health; Middlesex: 2016. NOAH Response to Final O’Neill AMR Review Report July 2016. Available online: https://www.noah.co.uk/wp-content/uploads/2016/07/FINAL-NOAH-response-to-final-O-Neill-review-25-07-16-cle.pdf (accessed on 27 June 2024).
  9. WHO Antimicrobial Resistance. 2021. Available online: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance (accessed on 27 June 2024).
  10. US Centres for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019; US Department of Health and Human Services: Atlanta, GA, USA, 2019; Available online: https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html (accessed on 27 June 2024).
  11. Prestinaci, F.; Pezzotti, P.; Pantosti, A. Antimicrobial resistance: A global multifaceted phenomenon. Pathog. Glob. Health 2015, 109, 309–318. [Google Scholar] [CrossRef] [PubMed]
  12. WHO. World Health Organization; Geneva: 2015. Global Action Plan on Antimicrobial Resistance. Available online: https://www.who.int/publications/i/item/9789241509763 (accessed on 27 June 2024).
  13. Arbune, M.; Gurau, G.; Niculet, E.; Iancu, A.V.; Lupasteanu, G.; Fotea, S.; Vasile, M.C.; Tatu, A.L. Prevalence of Antibiotic Resistance of ESKAPE Pathogens over Five Years in an Infectious Diseases Hospital from South-East of Romania. Infect. Drug Resist. 2021, 14, 2369–2378. [Google Scholar] [CrossRef] [PubMed]
  14. Ghenea, A.E.; Cioboată, R.; Drocaş, A.I.; Țieranu, E.N.; Vasile, C.M.; Moroşanu, A.; Țieranu, C.G.; Salan, A.-I.; Popescu, M.; Turculeanu, A.; et al. Prevalence and Antimicrobial Resistance of Klebsiella Strains Isolated from a County Hospital in Romania. Antibiotics 2021, 10, 868. [Google Scholar] [CrossRef] [PubMed]
  15. Barbu, I.C.; Gheorghe-Barbu, I.; Grigore, G.A.; Vrancianu, C.O.; Chifiriuc, M.C. Antimicrobial Resistance in Romania: Updates on Gram-Negative ESCAPE Pathogens in the Clinical, Veterinary, and Aquatic Sectors. Int. J. Mol. Sci. 2023, 24, 7892. [Google Scholar] [CrossRef]
  16. Szabó, S.; Feier, B.; Capatina, D.; Tertis, M.; Cristea, C.; Popa, A. An Overview of Healthcare Associated Infections and Their Detection Methods Caused by Pathogen Bacteria in Romania and Europe. J. Clin. Med. 2022, 11, 3204. [Google Scholar] [CrossRef] [PubMed]
  17. Chibelean, C.B.; Petca, R.-C.; Mareș, C.; Popescu, R.-I.; Enikő, B.; Mehedințu, C.; Petca, A. A Clinical Perspective on the Antimicrobial Resistance Spectrum of Uropathogens in a Romanian Male Population. Microorganisms 2020, 8, 848. [Google Scholar] [CrossRef] [PubMed]
  18. Petca, R.-C.; Mareș, C.; Petca, A.; Negoiță, S.; Popescu, R.-I.; Boț, M.; Barabás, E.; Chibelean, C.B. Spectrum and Antibiotic Resistance of Uropathogens in Romanian Females. Antibiotics 2020, 9, 472. [Google Scholar] [CrossRef] [PubMed]
  19. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 30th ed.; CLSI Supplement M100; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2020. [Google Scholar]
  20. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 31st ed.; CLSI Supplement M100; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2021. [Google Scholar]
  21. Axente, C.; Licker, M.; Moldovan, R.; Hogea, E.; Muntean, D.; Horhat, F.; Bedreag, O.; Sandesc, D.; Papurica, M.; Dugaesescu, D.; et al. Antimicrobial consumption, costs and resistance patterns: A two year prospective study in a Romanian intensive care unit. BMC Infect. Dis. 2017, 17, 358. [Google Scholar] [CrossRef] [PubMed]
  22. Mayr, F.B.; Yende, S.; Linde-Zwirble, W.T.; Peck-Palmer, O.M.; Barnato, A.E.; Weissfeld, L.A.; Angus, D.C. Infection Rate and Acute Organ Dysfunction Risk as Explanations for Racial Differences in Severe Sepsis. JAMA 2010, 303, 2495–2503. [Google Scholar] [CrossRef] [PubMed]
  23. Douglas, N.M.; Hennessy, J.N.; Currie, B.J.; Baird, R.W. Trends in Bacteremia Over 2 Decades in the Top End of the Northern Territory of Australia. Open Forum Infect. Dis. 2020, 7, ofaa472. [Google Scholar] [CrossRef] [PubMed]
  24. Karlowsky, J.A.; Jones, M.E.; Draghi, D.C.; Thornsberry, C.; Sahm, D.F.; Volturo, G.A. Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002. Ann. Clin. Microbiol. Antimicrob. 2004, 3, 7. [Google Scholar] [CrossRef] [PubMed]
  25. Li, K.; Li, L.; Wang, J. Distribution and Antibiotic Resistance Analysis of Blood Culture Pathogens in a Tertiary Care Hospital in China in the Past Four Years. Infect. Drug Resist. 2023, 16, 5463–5471. [Google Scholar] [CrossRef] [PubMed]
  26. Mancuso, G.; Midiri, A.; Gerace, E.; Marra, M.; Zummo, S.; Biondo, C. Urinary Tract Infections: The Current Scenario and Future Prospects. Pathogens 2023, 12, 623. [Google Scholar] [CrossRef] [PubMed]
  27. Ding, X.; Tang, Q.; Xu, Z.; Xu, Y.; Zhang, H.; Zheng, D.; Wang, S.; Tan, Q.; Maitz, J.; Maitz, P.K.; et al. Challenges and innovations in treating chronic and acute wound infections: From basic science to clinical practice. Burn. Trauma 2022, 10, tkac014. [Google Scholar] [CrossRef]
  28. Tom, I.M.; Ibrahim, M.M.; Umoru, A.M.; Umar, J.B.; Bukar, M.A.; Haruna, A.B.; Aliyu, A. Infection of Wounds by Potential Bacterial Pathogens and Their Resistogram. Open Access Libr. J. 2019, 6, 1–13. [Google Scholar] [CrossRef]
  29. Ahmed, E.F.; Rasmi, A.H.; Darwish, A.M.A.; Gad, G.F.M. Prevalence and resistance profile of bacteria isolated from wound infections among a group of patients in upper Egypt: A descriptive cross-sectional study. BMC Res. Notes 2023, 16, 106. [Google Scholar] [CrossRef] [PubMed]
  30. Han, Y.; Zhang, J.; Zhang, H.-Z.; Zhang, X.-Y.; Wang, Y.-M. Multidrug-resistant organisms in intensive care units and logistic analysis of risk factors. World J. Clin. Cases 2022, 10, 1795–1805. [Google Scholar] [CrossRef] [PubMed]
  31. Wroblewska, M.; Rudnicka, J.; Marchel, H.; Luczak, M. Multidrug-resistant bacteria isolated from patients hospitalised in Intensive Care Units. Int. J. Antimicrob. Agents 2006, 27, 285–289. [Google Scholar] [CrossRef] [PubMed]
  32. Ny, S.; Edquist, P.; Dumpis, U.; Gröndahl-Yli-Hannuksela, K.; Hermes, J.; Kling, A.-M.; Klingeberg, A.; Kozlov, R.; Källman, O.; Lis, D.O.; et al. Antimicrobial resistance of Escherichia coli isolates from outpatient urinary tract infections in women in six European countries including Russia. J. Glob. Antimicrob. Resist. 2019, 17, 25–34. [Google Scholar] [CrossRef] [PubMed]
  33. Evans, T. Diagnosis and management of sepsis. Clin. Med. 2018, 18, 146–149. [Google Scholar] [CrossRef] [PubMed]
  34. Kumar, A.; Roberts, D.; Wood, K.E.; Light, B.; Parrillo, J.E.; Sharma, S.; Suppes, R.; Feinstein, D.; Zanotti, S.; Taiberg, L.; et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock*. Crit. Care Med. 2006, 34, 1589–1596. [Google Scholar] [CrossRef] [PubMed]
  35. Draganescu, M.; Iancu, A.V.; Firescu, D.; Buzia, O.D.; Diaconu, C.; Rebegea, L. Trends in antimicrobials consumption and antimicrobial resistance in an infectious diseases hospital from the south-eastern region of Romania. Farmacia 2016, 64, 770–774. [Google Scholar]
  36. Tălăpan, D.; Sandu, A.-M.; Rafila, A. Antimicrobial Resistance of Staphylococcus aureus Isolated between 2017 and 2022 from Infections at a Tertiary Care Hospital in Romania. Antibiotics 2023, 12, 974. [Google Scholar] [CrossRef]
  37. Kaur, D.C.; Chate, S.S. Study of antibiotic resistance pattern in methicillin resistant Staphylococcus aureus with special reference to newer antibiotic. J. Glob. Infect. Dis. 2015, 7, 78–84. [Google Scholar] [CrossRef]
  38. Bassetti, S.; Tschudin-Sutter, S.; Egli, A.; Osthoff, M. Optimizing antibiotic therapies to reduce the risk of bacterial resistance. Eur. J. Intern. Med. 2022, 99, 7–12. [Google Scholar] [CrossRef]
  39. Cox, G.; Wright, G.D. Intrinsic antibiotic resistance: Mechanisms, origins, challenges and solutions. Int. J. Med. Microbiol. 2013, 303, 287–292. [Google Scholar] [CrossRef]
  40. Reygaert, W.C. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol. 2018, 4, 482–501. [Google Scholar] [CrossRef] [PubMed]
  41. La Fauci, V.; Alessi, V. Antibiotic resistance: Where are we going. Ann Ig 2018, 30 (Suppl. S1), 52–57. [Google Scholar] [CrossRef]
  42. National Research Council, Committee on Drug Use in Food Animals. The Use of Drugs in Food Animals: Benefits and Risks; National Academies Press: Washington, DC, USA, 1999. [Google Scholar]
Figure 1. Antibiotic resistance rates for bronchial aspirate cultures, catheter tip cultures, blood cultures and urocultures.
Figure 1. Antibiotic resistance rates for bronchial aspirate cultures, catheter tip cultures, blood cultures and urocultures.
Microorganisms 12 01517 g001
Figure 2. Escherichia coli, Klebsiella spp. and Staphylococcus aureus antibiotic resistance rates.
Figure 2. Escherichia coli, Klebsiella spp. and Staphylococcus aureus antibiotic resistance rates.
Microorganisms 12 01517 g002
Table 1. Recorded antibiotics.
Table 1. Recorded antibiotics.
Antibiotic ClassAntibiotic
AminoglycozidesGentamicin
Amikacin
CarbapenemsMeropenem
Imipenem
FluoroqinolonesCiprofloxacin
Levofloxacin
CephalosporinsCefepim
Ceftriaxone
Ceftazidime
Cefuroxime
LincosamidesClindamycin
GlicopeptidesVancomycin
PenicilinesAmoxicillin–clavulanic acid
Ampicillin
Oxacillin
Piperacillin-tazobactam
MonobactamesAztreonam
PolimixinesColistin
SulfonamidesTrimethoprim-sulfamethoxazole
OxazolidinonesLinezolid
Table 2. The age distributions of the patients with positive cultures.
Table 2. The age distributions of the patients with positive cultures.
Age GroupNumber of PatientsPercentage (%)
0–9 years2496.97
10–19 years852.32
20–29 years2276.36
30–39 years3028.25
40–49 years3138.55
50–59 years49213.44
60–69 years86223.56
70–79 years72819.9
80–89 years3439.37
90–100 years571.55
Table 3. Bacteria distribution stratified by culture type.
Table 3. Bacteria distribution stratified by culture type.
Number of CulturesNumber of Identified StrainsPAENSABCKLSTABSMPROVPROTCOCIEC
Uroculture13431098571937020983101467215585
Wound secretion culture73888512110313179316272169111084
Blood culture360381292518922812141174151
Bronchial aspirate culture22923528163704311651293218
Cervical culture214222422202356110700106
Sputum culture125122267270321120030014
Abscess culture11312221180291002180150
Vaginal culture921109926071100060042
Peritoneal liquid culture82806580131012030242
Catheter tip culture424445211413001004
Total3338329928699698204812211234216207921996
Percentages 8.562.9620.90.5914.46.623.681.250.476.20.260.6229.83
Legend: PA = Pseudomonas aeruginosa, EN = Enterobacter, SA = Staphylococcus aureus, BC = Bacillus cereus, KL = Klebsiella spp., ST= Streptococcus, AB= Acinetobacter baumanii, SM= Serratia marcesnens, PROV= Providencia, PROT= Proteus, CO = Corynebacterium, CI = Citrobacter, EC = Escherichia coli.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Chisavu, L.; Chisavu, F.; Marc, L.; Mihaescu, A.; Bob, F.; Licker, M.; Ivan, V.; Schiller, A. Bacterial Resistances and Sensibilities in a Tertiary Care Hospital in Romania—A Retrospective Analysis. Microorganisms 2024, 12, 1517. https://doi.org/10.3390/microorganisms12081517

AMA Style

Chisavu L, Chisavu F, Marc L, Mihaescu A, Bob F, Licker M, Ivan V, Schiller A. Bacterial Resistances and Sensibilities in a Tertiary Care Hospital in Romania—A Retrospective Analysis. Microorganisms. 2024; 12(8):1517. https://doi.org/10.3390/microorganisms12081517

Chicago/Turabian Style

Chisavu, Lazar, Flavia Chisavu, Luciana Marc, Adelina Mihaescu, Flaviu Bob, Monica Licker, Viviana Ivan, and Adalbert Schiller. 2024. "Bacterial Resistances and Sensibilities in a Tertiary Care Hospital in Romania—A Retrospective Analysis" Microorganisms 12, no. 8: 1517. https://doi.org/10.3390/microorganisms12081517

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop